You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,220,786


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,220,786
Title:Pharmaceutical composition of chelating complex micelles
Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.
Inventor(s): Wang; Chau-Hui (Kaohsiung, TW), Chen; Chia-Hung (New Taipei, TW), Lin; Johnson (Taipei, TW), Chen; Jing-Yi (Taipei, TW), Liao; Wei-Chuan (Kaohsiung, TW)
Assignee: ORIGINAL BIOMEDICALS CO., LTD (Tainan, TW)
Application Number:14/306,704
Patent Claims:1. A pharmaceutical composition of chelating complex micelles, comprising: a block copolymer with a chelating segment as a ligand and a dispersing segment; and a ligand-free metal ion core, the ligand-free metal ion core binds with the block copolymer by the chelating segment and the ligand-free metal ion core links a drug via coordinate bonding wherein the block copolymer is a poly(ethylene glycol)-b-poly(glutamic acid) (PEG-b-PGA), wherein the poly(glutamic acid) (PGA) is the chelating segment, and the poly(ethylene glycol)(PEG) is the dispersing segment.

2. The pharmaceutical composition of chelating complex micelles of claim 1, wherein the block copolymer is a Lewis base.

3. The pharmaceutical composition of chelating complex micelles of claim 1, wherein the ligand-free metal ion core is a Lewis acid.

4. The pharmaceutical composition of chelating complex micelles of claim 1, wherein the metal ion core is ferrous ion, ferric ion, or a trivalent gadolinium ion.

5. The pharmaceutical composition of chelating complex micelles of claim 1, wherein the drug contains Lewis base functional groups.

6. The pharmaceutical composition of chelating complex micelles of claim 1, wherein the drug is selected from the following groups of amifostine, WR-1065, doxorubicin, pemetrexed, gemcitabine, methotrexate, docetaxel, vinblastine, epirubicin, topotecan, irinotecan, ifosfamide, gefitinib, erlotinib, penicillin class, cloxacillin, dicloxacillin, gentamicin, vancomycin, amphotericin, quinolones, piperazine, fluoroquinolone, nalidixic acid, ciprofloxacin, levofloxacin, trovafloxacin, oseltamivir, metformin, trastuzumab, imatinib, rituximab, bevacizumab, celecoxib, etodolac, ibuprofen, cyclosporine, morphine, erythropoietin, granulocyte colony-stimulating factor, curcumin (enol, keto form), glutathione, Vitamin C, acetylcysteine, carnitine, galantamine, insulin, imipenem, cilastatin, ertapenem, meropenem, entecavir, telbivudine, lamivudine, melatonin, tocopherols, tocotrienol (Vitamin E), L-carnitine, carotenes, ubiquinol, lipoic acid, polyphenols, catecholamine, resveratrol, piceid, tempo, asarone, aminoguanidine, tocopherol monoglucoside, glycyrrhizic acid, epicatechin, flavonoid, orientin, vicenin, MPG (2-mercaptopropionyl glycine), Mesna (2-mercaptoethanesulfonic acid), and any combination thereof.

7. A pharmaceutical composition of chelating complex micelles, comprising: a block copolymer, wherein the copolymer is a Lewis base, and the copolymer comprises a chelating segment as a ligand, and a dispersing segment; a drug, which contains Lewis base functional groups; and a ligand-free metal ion core, wherein the ligand-free metal ion is a Lewis acid, and the ligand-free metal ion core binds with the block copolymer and the drug by the coordinate bonds wherein the block copolymer is poly(ethylene glycol)-b-poly(glutamic acid) (PEG-b-PGA), wherein the poly(glutamic acid) (PGA) is the chelating segment, and the poly(ethylene glycol)(PEG) is the dispersing segment.

8. The pharmaceutical composition of chelating complex micelles of claim 7, wherein the ligand-free metal ion core is ferrous ion, ferric ion, or a trivalent gadolinium ion.

9. The pharmaceutical composition of chelating complex micelles of claim 7, wherein the drug is selected from the following groups of amifostine, WR-1065, doxorubicin, pemetrexed, gemcitabine, methotrexate, docetaxel, vinblastine, epirubicin, topotecan, irinotecan, ifosfamide, gefitinib, erlotinib, penicillin class, cloxacillin, dicloxacillin, gentamicin, vancomycin, amphotericin, quinolones, piperazine, fluoroquinolone, nalidixic acid, ciprofloxacin, levofloxacin, trovafloxacin, oseltamivir, metformin, trastuzumab, imatinib, rituximab, bevacizumab, celecoxib, etodolac, ibuprofen, cyclosporine, morphine, erythropoietin, granulocyte colony-stimulating factor, curcumin (enol, keto form), glutathione, Vitamin C, acetylcysteine, carnitine, galantamine, insulin, imipenem, cilastatin, ertapenem, meropenem, entecavir, telbivudine, lamivudine, melatonin, tocopherols, tocotrienol (Vitamin E), L-carnitine, carotenes, ubiquinol, lipoic acid, polyphenols, catecholamine, resveratrol, piceid, tempo, asarone, aminoguanidine, tocopherol monoglucoside, glycyrrhizic acid, epicatechin, flavonoid, orientin, vicenin, MPG (2-mercaptopropionyl glycine), Mesna (2-mercaptoethanesulfonic acid), and any combination thereof.

Details for Patent 9,220,786

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2032-11-21
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2032-11-21
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2032-11-21
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2032-11-21
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2032-11-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.